Bortezomib is the first of its class to be approved for clinical use. It is a 26S proteosome inhibitor (26S proteosome is the principal regulator

Bortezomib is the first of its class to be approved for clinical use. It is a 26S proteosome inhibitor (26S proteosome is the principal regulator of the intracellular protein degradation that helps in cell proliferation and survival regulation).

Indications:

  • For the treatment of patients with multiple myeloma
  • For the treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy

 

Generic Name

Strength

Standard

Type

Packing

Pack Size

Bortezomib

2 mg

USP

INJ

Vial

 1 Vial